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Abstract
Background: Ki67 is widely used in order to distinguish the “A” and “B” subtypes of luminal-type breast cancer. This
study aimed to validate the prognostic value of adding p53 to Ki67 for characterizing luminal-type breast cancer.
Methods: Immunostaining for Ki67, p53, and the molecular markers HER2, CK5/6, CK14, EGFR, FOXA1, GATA3, and
P-cadherin was examined hormone receptor (HR)-positive cancer tissues from 150 patients. The prognostic value of
an immunohistochemical panel comprising Ki67 and p53 was compared with that of the single Ki67 labeling index
(LI), and uni- and multivariate analyses were performed.
Results: Division of the patients based on the immunohistochemistry results into favorable- (low Ki67 LI, p53-
negative) and unfavorable- (high Ki67 LI and/or p53-positive) phenotype groups yielded distinctly different Kaplan-
Meier's curves of both disease-free (P<0.0001) and overall survival (P=0.0007). These differences were much more
distinct than those between the corresponding low Ki67 LI vs. high Ki67LI curves. While the prognostic values of
the other molecular markers were not significant, combined Ki67-p53 status was an independent prognostic factor
by multivariate analysis.
Conclusion: These data indicate that an immunohistochemical panel comprising Ki67 and p53 is a practical tool for
management of patients with HR-positive breast cancer.
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Background
Approximately 70% of breast cancers express a hormone
receptor (HR). HR status is a powerful predictor of re-
sponse to therapies that inhibit estrogen synthesis or
block the action of its receptor [1]. Endocrine therapies
are established in the adjuvant setting [2-4]. For ex-
ample, women with node-negative, HR-positive breast
cancer who are treated with tamoxifen alone after sur-
gery have an average 10-year recurrence rate of only
15% [5]. If all of these patients were offered chemother-
apy, 85% would be over-treated [6]. It is therefore
important to distinguish patients with HR-positive
tumors at high risk for recurrence who need additional
chemotherapy from those for whom adjuvant hormonal
therapy alone may suffice [7].
Multi-gene assays are strong candidate tools for pre-
dicting the risk of recurrence in HR-positive patients.
For example, the Oncotype DX™ assay analyzes the ex-
pression levels of 21 genes (including 5 reference genes)
in formalin-fixed paraffin embedded tissues and pro-
duces a Recurrence Score (RS) that predicts the likeli-
hood of distant recurrence [6] and the benefit of
chemotherapy in women with early HR-positive breast
cancer [8]. Although Oncotype DX™ is a potentially
powerful tool for stratification of HR-positive patients, it
is too expensive to use in routine clinical practice. Many
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oncologists are eager for an alternative assay that is inex-
pensive as well as easy to use; one possible approach
would be an immunohistochemical (IHC) assay.
Sorlie et al. reported that breast cancers could be
divided, based on their gene expression profiles, into at
least 4 groups: luminal-type, HER2-type, normal-like-
type, and basal-type. Luminal-type cancers are character-
ized by an activated estrogen receptor (ER) signaling
pathway and are divided into 2 subtypes, luminal sub-
types “A” and “B. In general, luminal-subtype-A tumors
express higher levels of ER and carry a better prognosis
than do luminal-subtype-B tumors [9]. Recent studies
have shown that tumors of luminal subtype A have a
lower rate of p53 mutation [9-12] and are less prolifera-
tive [13,14] than those of luminal subtype B, suggesting
that the combination of p53 status and proliferation
markers could be useful to distinguish between luminal
subtypes A and B.
The tumor suppressor gene p53 plays a most import-
ant role in regulating normal cell fate in response to
various stresses, and disruption of p53 function is often
involved in tumor progression. Since the co-authors
first reported in 1991 that distinct immunoreaction
with p53 in the nuclei of breast cancer cells is an inde-
pendent prognostic indicator [15], more than 1000 arti-
cles about the correlation between p53 status and
breast cancer prognosis have been published. Recent
studies have shown that abnormalities of the p53 gene
[16] and accumulation of p53 protein in the nuclei
[17,18] are also robust prognostic indicators in HR-
positive patients.
Ki67 is the marker most often used to evaluate tumor
proliferation status. The Ki67 protein is a large (395 kD)
nuclear protein that is present during all active phases of
the cell cycle except for the G0 phase. Because prolifera-
tion status is closely correlated with tumor aggressive-
ness, the Ki67 labeling index (LI) is considered an
established prognostic marker for various tumor types,
including breast cancer [19,20]. Previous clinical studies
have revealed Ki67 LI to be a good prognostic indicator
for HR-positive breast cancer patients [7,21].
Although Ki67 is a strong prognostic indicator for
HR-positive breast cancer patients, adding Ki67 to the
commonly used indices in daily practice is controversial
[19]. Furthermore, its predictive value is weaker than
that of multi-gene expression assays such as Oncotype
DX™. In this study, we attempted to validate the classifi-
cation of HR-positive breast cancer patients by com-
bined analysis of Ki67 LI and p53 status. We performed
immunohistochemical examination of Ki67 and p53 ex-
pression in 150 samples of surgically resected HR-positive
invasive breast cancers and analyzed the relationships be-




Of the 247 patients who had undergone mastectomy or
breast-conserving surgery for invasive ductal carcinoma
of the breast at the National Defense Medical College
(NDMC) Hospital between 1995 and 1999, 150 patients
with ER-positive and/or progesterone-receptor (PgR)-
positive localized breast carcinomas were selected based
on immunohistochemical reevaluation of ER and PgR
expression. Tissue microarray (TMA) blocks of the
tumors from these 150 patients were constructed as pre-
viously described [22]. Briefly, double tissue cores 2 mm
in diameter were taken from each donor block, and
these core specimens were transferred to a recipient
block using a Tissue Microarrayer (Beecher Instruments,
Silver Spring, MD, USA). The use of the tissue blocks
was internally reviewed and approved by the NDMC
Ethics Committee.
The 150 patients had been followed up for a median
of 82 months (range, 1–151 months), during which time
there were 30 relapses and 15 deaths. In most cases, the
patients were prescribed adjuvant endocrine therapy (for
example, tamoxifen, toremifene, fadrozole, or LHRH
analogues). Forty-nine patients with large tumors and/or




(CMF), or oral fluoropyrimidines), and 12 patients with
locally advanced breast cancer had received preopera-
tive chemotherapy (for example, CAF or CEF). One
hundred forty-eight patients were females and 2 were
males. The clinical stage of the patients was determined
based on the TNM classification according to general
rules of the Japanese Breast Cancer Society [23]. Clini-
copathological data were obtained from the medical
records and pathology reports, but ER, PgR and HER2
status were examined in our previous study [22].
Immunohistochemistry
Immunohistochemistry was performed on a TMA com-
posed of 150 breast cancer tissue specimens. The antibodies
used were mouse monoclonal anti-p53 antibody (DO-7,
Dako, Glostrup, Denmark), mouse monoclonal anti-Ki67
antibody (MIB-1, Dako), mouse monoclonal anti-FOXA1
antibody (2D7, Abnova, Taipei, Taiwan), mouse monoclonal
anti-GATA3 antibody (HG3-31, Santa Cruz, Santa Cruz,
CA, USA) mouse monoclonal anti-CK5/6 antibody (D5/16
B4, Dako), mouse monoclonal anti-CK14 antibody (LL002,
NeoMarkers, Fremont, CA, USA), mouse monoclonal anti-
P-cadherin antibody (56C1, Novocastra, Newcastle, UK),
and a mouse monoclonal anti-EGFR antibody included in
an EGFR pharmDX kit (Dako).
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Sections (4-um-thick) were cut from the formalin-
fixed, paraffin-embedded TMA blocks. Antigens were
retrieved by microwave heating for 30 min in 10 mM so-
dium citrate (pH 6.0) for CK5/6 and GATA3 or by auto-
claving for 20 min in 10 mM Tris–HCl (pH 9.0) for
Ki67, p53, CK14, FOXA1, and P-cadherin. To block en-
dogenous peroxidase activity, the sections were treated
for 5 min with 100% methanol containing 3% H2O2.
Non-specific binding was blocked by incubation in 1%
normal swine serum (Dako) in phosphate-buffered sa-
line. The slides were incubated with primary antibodies
at 4°C overnight and then reacted with a dextran poly-
mer reagent combined with secondary antibodies and
peroxidase (Envision Plus; Dako) for 30 min at room
temperature. Specific antigen-antibody reactions were
visualized with 0.2% diaminobenzidine tetrahydrochlor-
ide and hydrogen peroxide. Immunostaining for EGFR
was performed in accordance with the package inserts of
the EGFR pharmDX Kit. The sections were counter-
stained with Mayer’s hematoxylin.
Evaluation of immunohistochemistry
Although there is no universal cut-off value for Ki67 LI,
Cheang et al. showed that, using the cases which were
subtyped by gene expression profile, the best Ki67 LI
cut-off value to distinguish luminal B from luminal A
was 13% [7]. Furthermore, similar to the 10% cut-off
value was used in several reports [21,24-28]. So, in this
study, Ki67 LI greater than 10% was classified as high.
The Ki67 LI was calculated as the percentage of positive
tumor nuclei divided by the total number of tumor cells
examined on the basis of a manual count of 500 or more
cells under high power (400×).
For p53, FOXA1, and GATA3, cells with immunos-
taining in the nucleus were defined as positive, while for
CK5/6, CK14, and P-cadherin, cells with immunostain-
ing along the cellular periphery and/or in the cytoplasm
were defined as positive. For p53, positive staining of
fewer than 10% of the tumor cells was defined as nega-
tive tumor expression and staining of 10% or more of
the tumor cells as positive tumor expression [15]. For P-
cadherin, membrane staining of fewer than 50% of the
tumor cells was defined as negative tumor expression
and staining of 50% or more of the tumor cells as posi-
tive tumor expression. P-cadherin positive tumors were
further divided into “weakly” and “strongly” expressing
tumors based on staining intensity. Finally, negative and




Figure 1 Representative images of immunostaining for 9 molecular markers. A, Positive nuclear Ki67 staining. The Ki67 labeling index of
this specimen is 12%. B, p53 staining in the nucleus. This tumor was scored as p53-positive. C, Positive HER2 membrane staining. The HER2
expression of this tumor was scored as 3+. D, Positive nuclear FOXA1 staining. This tumor was classified as FOXA1-positive. E, Positive nuclear
GATA3 staining. This tumor was classified as GATA3-positive. F, Positive CK5/6 membrane or sub-membrane staining of tumor cells. This tumor
was classified as CK5/6-positive. G, Positive CK14 membrane or sub-membrane staining of tumor cells. This tumor was classified as CK14-positive.
H, Positive EGFR membrane staining of tumor cells. The EGFR expression of this tumor was scored as 3+. I, Positive P-cadherin membrane or sub-
membrane immunoreactivity of tumor cells. This tumor was classified as P-cadherin-high. The magnification of all figures is ×400.
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Total Low Ki67 LIand Negative p53 High Ki67 LI and/or Positive p53 P - value
(n=150) (n=88) (n=62)
Age
≦50 71 40 31
>50 79 48 31 0.58
Tumor size
<5.0 cm 128 78 50
≧5.0 cm 19 8 11 0.12
Unknown 3 2 1
Lymph node metastasis
(−) 84 52 32
(+) 63 34 29 0.33
Unknown 3 2 1
Stage
I or II 129 78 51
III 17 7 10 0.13
Unknown 4 3 1
Nuclear grade
1, 2 115 76 39
3 35 12 23 0.0008
HER2 status
Negative 142 88 54
Positive 8 0 8 0.0006
Basal phenotype marker (CK5/6, CK14, EGFR)
Negative 140 87 53
Positive 10 1 9 0.0016
FOXA1
Negative 20 14 6
Positive 127 72 55 0.38
NE 3 2 1
GATA3
Negative 30 18 12
Positive 120 70 50 0.99
P-cadherin
Low 94 62 32
High 56 26 30 0.0019
Chemotherapy
No 98 59 39 0.59
Yes 52 29 23
Abbreviation: LI labeling index, NE not evaluable.
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“low” and strongly P-cadherin-staining tumors as “high”.
A tumor expression cutoff point of 10% of cells stained
was used for GATA3, CK5/6, and CK14 and a cutoff of
70% of cells stained for FOXA1, regardless of staining
intensity. An EGFR score of 0–3+ was assigned accord-
ing to the manufacturer’s package insert, and scores of
1–3+ were classified as positive. CK5/6, CK14, and
EGFR were considered basal phenotype markers.
ER and PgR were examined immunohistochemically as
described in the previous study [22], using mouse mono-
clonal anti-human ER (clone 1D5, Dako) and mouse
anti-human PgR (clone PgR636, DAKO). ER and PgR
were defined as positive if the nuclear staining was seen
in 10% or more of tumor cells. Hormone receptor posi-
tive was defined as at least one of ER or PgR positive,
and hormone receptor negative was defined as ER and
PgR negative. HER2 was evaluated by IHC using rabbit
polyclonal anti-HER2 antibody (HercepTest kit, Dako)
and FISH (in case of IHC 2+) using Path Vysion kit
(Abbott Park, IL, USA). HER2 was defined as positive if
the IHC score was “3+” according to the standard pro-
cedure, or gene amplification (HER2:CEP17 ratio > 2.0)
was detected by FISH [29].
The immunohistochemistry results were evaluated in-
dependently by 2 observers (TK and KI), and cases with
disparate scores were re-evaluated and discussed until a
consensus was reached. Ki67-positive cells were counted
and the labeling index calculated by TK alone.
Statistical analysis
Comparisons between groups were evaluated with the
chi-squared test or Fisher’s exact test. Patient survival
curves were drawn using the Kaplan-Meier method and
analyzed by the log-rank test. The hazard ratios and cor-
responding 95% confidence intervals (CIs) were calcu-
lated with Cox’s proportional hazards model. Univariate
and multivariate Cox’s proportional hazards models were
used to explore the associations of variables with
disease-free and overall survival. For all tests, differences
at P < 0.05 were considered statistically significant. All
analyses were performed using the software JMP 6.0 for
Windows (SAS Institute Inc., Cary, NC, USA).
Results
Expression of markers (Ki67, p53, HER2, FOXA1, GATA3,
CK5/6, CK14, EGFR, and P-cadherin) in HR-positive tumors
(n=150)
Representative images of immunostaining for the mar-
kers examined in this study are shown in Figure 1.
Among 150 HR-positive tumors, there were 51 (34%)
Ki67 LI-high tumors, 22 (15%) p53-positive tumors, 127
(85%) FOXA1-positive tumors, 120 (80%) GATA3-
HR, 3.6; 95%CI, 1.7-7.9; log-rank P = 0.0004
Low ki67 LI (n=98)
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Figure 2 Prognostic impact of Ki67 labeling index (LI) and p53 status in patients with hormone receptor-positive and HER2-negative
breast cancer (n=142). A, Disease free survival curves for 98 patients with Ki67 LI-low tumors and 44 patients with Ki67 LI-high tumors. The 2
curves differ significantly (HR, 3.6; 95% CI, 1.7–7.9; log-rank P = 0.0004). B, Overall survival curves for 98 patients with Ki67 LI-low tumors and 44
patients with Ki67 LI-high tumors. The 2 curves differ significantly (HR, 4.4; 95% CI, 1.3–14.6; log-rank P = 0.0082). C, Disease-free survival curves for
122 patients with p53-negative tumors and 20 patients with p53-positive tumors. The 2 curves differ significantly (HR, 5.2; 95% CI, 2.3–11.9; log-
rank P < 0.0001). D, Overall survival curves for 122 patients with p53-negative tumors and 20 patients with p53-positive tumors. The 2 curves
differ significantly (HR, 5.7; 95% CI, 1.8–18.0; log-rank P = 0.0008).
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positive tumors, and 6 (4%) CK5/6-positive, 3 (2%)
CK14-positive, 3 (2%) EGFR-positive, and 56 (37%) P-
cadherin-high tumors. Ten (7%) tumors showed positive
staining for at least 1 of the basal phenotype markers
CK5/6, CK14, and EGFR. Eight tumors were determined
as HER2-positive, which were composed of 6 tumors
with IHC 3+ and 2 tumors with IHC 2+ and FISH +.
Correlations of clinicopathological factors (tumor size,
lymph-node status, nuclear grade, and molecular
markers) with Ki67 LI status and p53 immunoreactivity in
HR-positive tumors (n=150)
The tumors with high Ki67 LIs showed significantly
higher frequencies of high nuclear grade, HER2 positiv-
ity, basal phenotype marker positivity, and P-cadherin
(P = 0.013, P = 0.0010, and P = 0.0015, and P = 0.013,
respectively). The tumors with positive p53 staining
showed significantly higher frequencies of large tumor
size and high nuclear grade (P = 0.0013 and P = 0.035,
respectively).
Correlation between clinicopathological factors and
combined Ki67-p53 status in HR-positive tumors (n=150)
There were 88 (59%), 11 (7%), 40 (27%), and 11 (7%)
tumors with the Ki67 LI-low and p53-negative, Ki67 LI-
low and p53-positive, Ki67 LI-high and p53-negative,
and Ki67 LI-high and p53-positive phenotypes, respect-
ively. The tumors with the “favorable” Ki67 LI-low and
p53-negative phenotype (n = 88) showed lower frequen-
cies of high nuclear grade, HER2 positivity, basal pheno-
type marker positivity, and high P-cadherin expression
(P = 0.0008, P = 0.0006, P = 0.0016 and P = 0.0019, re-
spectively; Table 1) than did those with “unfavorable”
Ki67 LI-low and p53-positive (n = 11), Ki67 LI-high and
Table 2 Univariate and multivariate analyses of immunohistochemical parameters (disease-free survival and overall
survival)
Univariate Multivariate
Total (n=142) Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Disease-free survival
Ki67 LI Low 98 1 1
High 44 3.6 1.7-7.9 0.0010 3.2 1.4-7.6 0.0073
p53 Negative 122 1 1
Positive 20 5.2 2.3-11.9 <0.0001 3.9 1.6-9.4 0.0025
FOXA1 Low 20 1 1
High 119 1.4 0.51-3.6 0.54 1.7 0.56-5.2 0.34
GATA3 Negative 30 1 1
Positive 112 1.5 0.65-3.5 0.34 1.2 0.46-3.4 0.66
Basal phenotype marker Negative 133 1 1
(CK5/6, CK14, EGFR) Positive 9 1.0 0.24-4.3 0.98 0.47 0.10-2.2 0.34
P-cadherin Low 90 1 1
High 52 1.3 0.59-2.8 0.52 0.87 0.37-2.1 0.75
Overall survival
Ki67 LI Low 98 1 1
High 44 4.4 1.3-14.6 0.016 3.2 0.91-11.9 0.070
p53 Negative 122 1 1
Positive 20 5.7 1.8-18.0 0.0029 3.8 1.1-13.0 0.030
FOXA1 Low 20 1 1
High 119 0.49 0.06-3.9 0.50 0.75 0.07-7.5 0.81
GATA3 Negative 30 1 1
Positive 112 1.1 0.31-4.3 0.84 1.3 0.29-6.1 0.70
Basal phenotype marker Negative 133 1 1
(CK5/6, CK14, EGFR) Positive 9 1.2 0.15-9.3 0.86 0.60 0.07-5.4 0.64
P-cadherin Low 90 1 1
High 52 1.8 0.57-5.5 0.32 1.2 0.36-4.2 0.73
Abbreviation: 95% CI 95% confidence interval, LI labeling index.
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p53-negative (n = 40), and Ki67 LI-high and p53-
positive (n = 11) phenotypes (n = 62 total). Interestingly,
all HER2-positive tumors were shown to be unfavorable
phenotype tumors. This study found no correlations be-
tween the combined Ki67-p53 status and the clinical fac-
tors tumor size, nodal status.
Prognostic implications of combined Ki67-p53 status in
HR-positive and HER2-negative tumors (n=142)
The patients with HER2-positive tumors could be
received anti-HER2 treatments which have tremendous
effect in both adjuvant and metastatic setting [30,31]. So,
we next conducted the further analyses using the cases
with HR-positive and HER2-negative tumors in order to
evaluate more definitely the clinical implication of Ki67
and p53.
Both the disease-free survival (DFS) and overall sur-
vival (OS) curves differed significantly between the
patients with Ki67 LI-low tumors and those with Ki67-
LI-high tumors (DFS: HR, 3.6; 95% CI, 1.7–7.9; log-rank
P = 0.0004; Figure 2A, and OS: HR, 4.4; 95% CI, 1.3–
14.6; log-rank P = 0.0082; Figure 2B). Both curves also
differed significantly between the patients with p53-
negative tumors and those with p53-positive tumors
(DFS: HR, 5.2; 95% CI, 2.3–11.9; log-rank P < 0.0001;
Figure 2C, and OS: HR, 5.7; 95% CI, 1.8–18.0; log-rank
P = 0.0008; Figure 2D). Furthermore, a multivariate ana-
lysis using Cox’s proportional hazard model and inclu-
ding immunostaining for the markers Ki67, p53,
HER2, FOXA1, GATA3, the basal phenotype markers,
and P-cadherin selected Ki67 and p53 as significant prog-
nostic factors for DFS (P = 0.0073 and P = 0.0025, respect-
ively; Table 2) and p53 for OS (P = 0.030, Table 2).
Figures 3A and 3B show the DFS and OS curves for
the 4 combined Ki67-p53 status groups. Patients with
Ki67 LI-low and p53-negative tumors survived longer
than those in the other 3 groups (the patients with Ki67
LI-low and p53-positive tumors, Ki67-high and p53-
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Figure 3 Prognostic impact of combined Ki67-p53 status in patients with hormone receptor-positive and HER2-negative breast cancer
(n=142). A, Disease-free survival curves for 88 patients with Ki67 LI-low and p53-negative tumors, 34 patients with Ki67 LI-high and p53-negative
tumors, 10 patients with Ki67 LI-low and p53-positive tumors, and 10 patients with Ki67 LI-high and p53-positive tumors. Patients with Ki67 LI-low
and p53-negative tumors had significantly longer disease-free survival than those with Ki67 LI-low and p53-positive tumors, those with Ki67 LI-
high and p53-negative tumors, or those with Ki67 LI-high and p53-positive tumors (P < 0.0001, P < 0.0001, and P = 0.0005, respectively). B,
Overall survival curves for 88 patients with Ki67 LI-low and p53-negative tumors, 34 patients with Ki67 LI-high and p53-negative tumors, 10
patients with Ki67 LI-low and p53-positive tumors, and 10 patients with Ki67 LI-high and p53-positive tumors. Patients with Ki67 LI-low and p53-
negative tumors had significantly longer disease-free survival than those with Ki67 LI-low and p53-positive tumors, those with Ki67 LI-high and
p53-negative tumors, or those with Ki67 LI-high and p53-positive tumors (P = 0.0010, P = 0.011, and P < 0.0001, respectively). C, Disease-free
survival curves for patients with favorable-phenotype tumors (88 patients with Ki67 LI-low and p53-negative tumors) and unfavorable-phenotype
tumors (54 patients with Ki67 LI-high and/or p53-positive tumors). The disease-free survival time was significantly longer in the favorable-
phenotype group than in the unfavorable-phenotype group (HR, 9.3; 95% CI, 3.5–24.5; P < 0.0001). D, Overall survival curves for patients with
favorable-phenotype tumors (88 patients with Ki67 LI-low and p53-negative tumors) and those with unfavorable-phenotype tumors (54 patients
with Ki67 LI-high and/or p53-positive tumors). The disease-free survival was significantly longer in the favorable-phenotype group than in the
unfavorable-phenotype group (HR, 8.8; 95% CI, 1.9–40.4; P = 0.0007).
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negative tumors, and Ki67-high and p53-positive tumors)
in both the DFS (P < 0.0001, P < 0.0001, and P = 0.0005,
respectively; Figure 3A) and OS (P = 0.0010, P = 0.011,
and P < 0.0001, respectively; Figure 3B) analyses. The DFS
and OS curves therefore differed significantly between the
patients with favorable-phenotype tumors and those with
unfavorable-phenotype tumors (DFS: HR, 9.3; 95% CI,
3.5–24.5; log-rank P < 0.0001; Figure 3C, and OS: HR, 8.8;
95% CI, 1.9–40.4; log-rank P = 0.0007; Figure 3D). This
difference was much more distinct than that between the
low- and high-Ki67-LI curves (DFS: HR, 3.6; 95% CI, 1.7–
7.9, and OS: HR, 4.4; 95% CI, 1.3–14.6). The 5- and 10-
year OS rates were 97% and 97%, respectively, for the
patients with favorable-phenotype tumors but only 91%
and 65%, respectively, for the patients with unfavorable-
phenotype tumors.
We next conducted subgroup analysis of HR-positive
and HER2-negative breast cancer patients who had and
had not received pre- or post-operative chemotherapy.
Among the 49 patients who had received chemotherapy,
those with favorable-phenotype tumors had significantly
longer DFS than those with unfavorable-phenotype
tumors (P < 0.0001). And then, among the 93 patients
who had not received chemotherapy, those with
favorable-phenotype tumors had significantly or almost
significantly longer DFS than those with unfavorable-
phenotype tumors (P = 0.0002).
Finally, we performed multivariate analyses of survival
using Cox’s model of the proportional hazards regression
including immunohistochemical parameters (combined
Ki67-p53 status, FOXA1, GATA3, basal phenotype mar-
ker and P-cadherin) and the established clinicopatholo-
gical factors (tumor size, lymph-node metastasis, nuclear
grade and chemotherapy).
In those analyses, combined Ki67-p53 status, tumor size
and chemotherapy was a significant prognostic indicators
of DFS (P < 0.0001, P = 0.0001 and P = 0.0028, respectively;
Table 3) and combined Ki67-p53 status was an only signifi-
cant prognostic indicator of OS (P = 0.0081, Table 4).
Discussion
The international expert panel at the 2009 St. Gallen
Consensus meeting referred to the importance of prolif-
eration markers in deciding whether to include adjuvant
chemotherapy in the treatment of patients with HR-
positive HER-2-negative breast cancers. Several large-
scale studies have evaluated the clinical significance of
the Ki67 LI among patients with HR-positive breast can-
cer [7,18,21]. In this study, we showed that an IHC panel
comprising p53 status and Ki67 LI is more accurate than
Ki67 LI alone at predicting the prognosis for patients
with HR-positive and HER2-negative breast cancer.
The results of our IHC panel divided the patients with
HR-positive and HER2-negative invasive breast cancers into
Table 3 Univariate and multivariate analyses of disease-free survival in patients with hormone receptor-positive/HER2-
negative primary breast cancer
Univariate Multivariate
Total (n=142) Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Ki67-p53 Low Ki67 LI and Negative p53 88 1 1
High Ki67 LI and/or Positive p53 54 9.3 3.5-24.5 < 0.0001 11.6 4.2-32.3 < 0.0001
FOXA1 Low 20 1
High 119 1.4 0.51-3.6 0.54
GATA3 Negative 30 1
Positive 112 1.5 0.65-3.5 0.34
Basal phenotype marker Negative 9 1
(CK5/6, CK14, EGFR) Positive 133 1.0 0.24-4.3 0.98
P-cadherin Low 90 1
High 52 1.3 0.59-2.8 0.52
Tumor size <5.0 cm 17 1 1
≧5.0 cm 122 4.9 2.1-11.4 0.0003 5.7 2.3-14.1 0.0002
Lymph-node metastasis (−) 80 1
(+) 59 3.8 1.6-8.8 0.0020
Nuclear grade 1, 2 111 1
3 31 4.2 1.9-9.0 0.0002
Chemotherapy No 93 1 1
Yes 49 2.6 1.2-5.7 0.014 3.5 1.5-7.9 0.0028
Abbreviation: 95%CI 95% confidence interval, LI labeling index.
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2 distinct prognostic subtypes, those with favorable-
phenotype (Ki67 LI-low and p53-negative) and unfavorable-
phenotype group (Ki67 LI-high and/or p53-positive)
tumors. Multivariate analysis showed that the IHC panel
results, tumor size and chemotherapy were independent
prognostic factors for DFS and that the IHC panel results
was an only independent prognostic factor for OS. Further-
more, 76 of the 78 patients (97%) with early-clinical-stage (I
or II) cancers showing the favorable phenotype were alive at
the end of this study. The results of a similar immunohisto-
chemical biomarker panel for 6 markers, including p53 and
Ki67, were reported by Brian et al. to be a significant prog-
nostic factor [32]. Ross et al. also showed that the immuno-
histochemical detection of 5 markers, including p53, was
significantly associated with clinical outcome [33]. These
reports support our data, at least in part; moreover, our
immunohistochemical panel using 2 easy-to-use antibodies
(Ki67 and anti-p53 antibodies) was both simpler than the
cited panels. Miller et al. reported the similar results to this
reports [24]. They evaluated the three molecular marker
(Ki67, p53 and HER2) using the whole cases with HR-
positive tumors. On the other hand, we excluded the HER2-
positive tumors from the whole HR-positive tumors and
then evaluate the clinicopathological implication of com-
bined Ki67-p53 status in the patients with HR-positive and
HER2-negative tumors. Nowadays, the patients with HER2-
positive tumors are treated with anti-HER2 drugs and show
different clinical outcome to those with HER2-negative
tumors. So, our results give the more precise information
and are more applicable to the dairy practice than the
results of Miller et al.
The results of the immunohistochemical panel divided
the HR-positive and HER2-negative breast cancer patients
as follows: the 10-year DFS rates were 81% for the favor-
able phenotype group and 46% for the unfavorable pheno-
type group, while the 10-year OS rates were 97% and 65%
for the favorable and unfavorable phenotype groups, re-
spectively. To exclude the influence of adjuvant chemo-
therapy on the predictive value of the panel, we examined
the prognostic significance of the panel separately in
patients who received either pre- or post- operative
chemotherapy and those who received no chemotherapy.
As the immunohistochemical panel results were also iden-
tified as a significant prognostic factor in the patients who
did not receive chemotherapy, we were able to exclude
the influence of chemotherapy on our results. Our data in-
dicate that patients with favorable-phenotype cancers have
a clinical choice to avoid cytotoxic chemotherapy, as the
baseline prognosis with adjuvant hormonal therapy alone
is very good for this group.
In this report, the unfavorable phenotype-tumors
exhibited significantly higher rates of positivity for
Table 4 Univariate and multivariate analyses of overall survival in patients with hormone receptor-positive/HER2-
negative primary breast cancer
Univariate Multivariate
Total Hazard (95% CI) P-value Hazard (95%CI) P-value
(n=142) ratio ratio
Ki67-p53 Low Ki67 LI and Negative p53 88 1 1
High Ki67 LI and/or Positive p53 54 8.8 1.9-40.4 0.0049 7.9 1.7-36.7 0.0081
FOXA1 Low 20 1
High 119 0.49 0.06-3.9 0.50
GATA3 Negative 30 1
Positive 112 1.1 0.31-4.3 0.84
Basal phenotype marker Negative 9 1
(CK5/6, CK14, EGFR) Positive 133 1.2 0.15-9.3 0.86
P-cadherin Low 90 1
High 52 1.8 0.57-5.5 0.32
Tumor size <5.0cm 17 1
≧5.0cm 122 3.4 0.90-12.8 0.071
Lymph-node metastasis (−) 80 1
(+) 59 3.9 1.02-14.7 0.045
Nuclear grade 1, 2 111 1
3 31 3.8 1.2-11.9 0.0020
Chemotherapy No 93 1
Yes 49 2.0 0.65-6.3 0.22
Abbreviation: 95%CI 95% confidence interval, LI labeling index.
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HER2, basal phenotype markers (CK5/6, CK14, and
EGFR), and P-cadherin than did the favorable-phenotype
tumors. P-cadherin has been previously shown to be
overexpressed on basal-type tumors [14,34]. These prop-
erties suggest that unfavorable-phenotype tumors take
on not only the “HER2” phenotype [7] but also the
“basal” phenotype. To our knowledge, this is the first
clinical study to reveal an obvious correlation between
luminal subtype-B and basal-type breast tumors. Basal-
type tumors exhibit more p53 mutations [9,35] and nu-
clear p53 protein accumulation [36] than do luminal-
type or HER2-type tumors, so p53 mutation is thought
to be one of the characteristics of basal-type tumors
[37,38]. Our results would be consistent with this view-
point. We suspect that some tumors should be consid-
ered “mixed intrinsic subtype” tumors, that is, tumors
that exhibit characteristics of 2 or more intrinsic sub-
types and therefore cannot be classified as any “pure” in-
trinsic subtype.
Conclusions
In conclusion, our results revealed that the cases with
Ki67 LI-high and p53 positive showed a mixed tendency
towards the “HER2” and “basal” types ,and that a simple
immunohistochemical panel comprising Ki67 and p53
could distinguish between the cases with a favorable
phenotype group and those with an unfavorable pheno-
type group among HR-positive and HER2-negative
breast cancer patients. These suggest that our simple
immunohistochemical panel comprising Ki67 and p53 is
a promising tool for distinguishing between “luminal-
subtype-A” and “luminal-subtype-B” breast cancers and
management of patients with HR-positive breast cancer.
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